Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00366834 · ClinicalTrials.gov registry record · Phase 3
Intravenous And Oral Casopitant (GW679769) For The Prevention Of Chemotherapy Induced Nausea And Vomiting
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,840
- Enrollment target
NCT00366834: Completed Phase 3 study, sponsored by GlaxoSmithKline.
NCT00366834 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 1,840 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (138% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00366834, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,840 participants
- Enrollment target
Study Summary
This is a Phase III trial designed to demonstrate that casopitant (GW679769) plus dexamethasone and ondansetron is more effective in the prevention of vomiting than dexamethasone and ondansetron alone following the administration of moderately emetogenic chemotherapy.
Interventions
- DRUG placebo
- DRUG Casopitant (GW679769) oral tablets
- DRUG Casopitant (GW679769) intravenous
- DRUG Dexamethasone intravenous
- DRUG Ondansetron oral tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,840 participants |
| Start Date | 2006-07 |
| Est. Completion | 2009-10 |
| Phase | Phase 3 |
What the finished NCT00366834 record still lists
NCT00366834 is an interventional study that assigns participants to a tested intervention. Its 1,840 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (138% higher).
The record links to 0 conditions, and to 5 interventions - of which placebo is the first listed.
NCT00366834 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00366834 about?
NCT00366834 is a clinical study titled "Intravenous And Oral Casopitant (GW679769) For The Prevention Of Chemotherapy Induced Nausea And Vomiting". This is a Phase III trial designed to demonstrate that casopitant (GW679769) plus dexamethasone and ondansetron is more effective in the prevention of vomiting than dexamethasone and ondansetron alone following the administration of moderately emetogenic chemotherapy.
What is the current status of trial NCT00366834?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,840 participants. The study started on 2006-07. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00366834?
The interventions under investigation include: placebo (DRUG), Casopitant (GW679769) oral tablets (DRUG), Casopitant (GW679769) intravenous (DRUG), Dexamethasone intravenous (DRUG), Ondansetron oral tablets (DRUG).
Who is sponsoring clinical trial NCT00366834?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00366834's enrollment target sits among peer trials
1,840 114th of 2000 higher than 1,885 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06740630 · 1,840 participants · Phase 3
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age
- NCT07104240 · 1,836 participants · NA
A Vaccine Promotion Package (TweenVax) to Improve Adolescent HPV Vaccination, TweenVax Trial
- NCT06465810 · 1,850 participants
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
- NCT06580080 · 1,850 participants · NA
Evaluation of Are You Ready?
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia